AQR Capital Management - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,538,958
+269.6%
137,776
+608.1%
0.00%
+200.0%
Q2 2023$416,358
+3.3%
19,456
+95.2%
0.00%0.0%
Q1 2023$403,025
-49.7%
9,966
-42.1%
0.00%
-50.0%
Q4 2022$801,400
+59.0%
17,227
+77.3%
0.00%
+100.0%
Q3 2022$504,000
+42.4%
9,719
+29.8%
0.00%0.0%
Q2 2022$354,000
-37.8%
7,490
-6.3%
0.00%0.0%
Q1 2022$569,000
-46.1%
7,993
-43.4%
0.00%
-50.0%
Q4 2021$1,055,000
+182.8%
14,113
+115.2%
0.00%
+100.0%
Q3 2021$373,000
+6.3%
6,559
-17.7%
0.00%0.0%
Q2 2021$351,000
-12.9%
7,966
-2.5%
0.00%0.0%
Q1 2021$403,000
-73.3%
8,174
-77.2%
0.00%
-66.7%
Q4 2020$1,507,000
-25.5%
35,797
-19.0%
0.00%0.0%
Q3 2020$2,023,000
-35.2%
44,197
-29.0%
0.00%
-40.0%
Q2 2020$3,124,000
-22.1%
62,226
-20.2%
0.01%
-28.6%
Q1 2020$4,009,000
-43.7%
77,955
-32.3%
0.01%
-12.5%
Q4 2019$7,119,000
-14.0%
115,231
-16.4%
0.01%
-20.0%
Q3 2019$8,281,000
-20.9%
137,835
+11.1%
0.01%
-16.7%
Q2 2019$10,472,000
-23.1%
124,103
-12.9%
0.01%
-14.3%
Q1 2019$13,618,000
+2.4%
142,564
-24.1%
0.01%
-6.7%
Q4 2018$13,302,000
+20.3%
187,799
+45.2%
0.02%
+36.4%
Q3 2018$11,053,000
-20.8%
129,336
+7.4%
0.01%
-21.4%
Q2 2018$13,954,000
+29.3%
120,400
-9.8%
0.01%
+16.7%
Q1 2018$10,795,000
+18.5%
133,409
-14.0%
0.01%
+20.0%
Q4 2017$9,106,000
+23.2%
155,182
-1.8%
0.01%
+11.1%
Q3 2017$7,394,000
+49.2%
157,993
+14.7%
0.01%
+28.6%
Q2 2017$4,955,000
+29.7%
137,723
+11.0%
0.01%
+40.0%
Q1 2017$3,820,000
+0.2%
124,054
+9.0%
0.01%0.0%
Q4 2016$3,812,000
+38.0%
113,794
+9.6%
0.01%
+25.0%
Q3 2016$2,763,000
+170.9%
103,817
+124.4%
0.00%
+100.0%
Q2 2016$1,020,000
-20.1%
46,258
+6.5%
0.00%0.0%
Q1 2016$1,276,000
-24.2%
43,436
-14.8%
0.00%
-33.3%
Q4 2015$1,684,000
-14.5%
51,003
-6.4%
0.00%
-25.0%
Q3 2015$1,969,000
-11.1%
54,474
+10.6%
0.00%0.0%
Q2 2015$2,216,000
+74.5%
49,248
+18.8%
0.00%
+33.3%
Q1 2015$1,270,000
-57.7%
41,462
-29.7%
0.00%
-50.0%
Q4 2014$2,999,000
+28.0%
58,980
-0.4%
0.01%0.0%
Q3 2014$2,343,000
+160.3%
59,200
+183.3%
0.01%
+200.0%
Q2 2014$900,00020,9000.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders